Key result
Spironolactone therapy for ≥6 months in patients with nonischemic dilated cardiomyopathy improved subendocardial myocardial perfusion reserve index from 1.63 at baseline to 1.80 (P<0.001).
Why the study?
Does spironolactone added to standard heart failure therapy improve left ventricular energy supply-demand relations in patients with nonischemic dilated cardiomyopathy?
Population
12 patients with nonischemic dilated cardiomyopathy (NIDCM)
Comparison
Spironolactone added to a standard heart failure… vs Baseline measurements prior to spironolactone…
Design
Cohort
Follow-up
≥6 months
Authors
Loading...
Spironolactone was associated with improved perfusion reserve in nonischemic cardiomyopathy; hypothesis-generating and should not yet change practice.
Does spironolactone added to standard heart failure therapy improve left ventricular energy supply-demand relations in patients with nonischemic dilated cardiomyopathy?
Absolute Event Rate: 1.8% vs 1.63%
p-value: p=<0.001
Spironolactone added to standard heart failure therapy improves myocardial perfusion, oxidative metabolism, and left ventricular performance in patients with nonischemic dilated cardiomyopathy.
Bell et al. (2014) studied Nonischemic dilated cardiomyopathy (NIDCM) (n=12). Spironolactone vs. Baseline was evaluated on Subendocardial myocardial perfusion reserve index (MPRI) (p=<0.001). Spironolactone therapy for ≥6 months in patients with nonischemic dilated cardiomyopathy improved subendocardial myocardial perfusion reserve index from 1.63 at baseline to 1.80 (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: